L. Kiss

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
László E. Kiss, Laszlo E Kiss, László E. Kiss, László E Kiss, Laszlo Erno Kiss, L Kiss, László Kiss, Laszlo Kiss
Publication record
54 papers · 1,761 citations · H-index 21

PAPERS

22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy
20230 citationsauthor #5
531. GM-1020 is a Novel, Orally Bioavailable NMDA Antagonist With Improved Separation Between Antidepressant and Ataxic Doses Compared to Ketamine
20230 citationsauthor #7
527. GM-2040 is a Novel Putative Non-Hallucinogenic 5-HT2A Agonist With Attenuated Head Twitch and Retained Antidepressant Activity
20230 citationsauthor #6
Absorption, metabolism and excretion of opicapone in human healthy volunteers
20227 citationsauthor #7
HTS-based discovery and optimization of novel positive allosteric modulators of the α7 nicotinic acetylcholine receptor.
20212 citationsauthor #8
Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping
20214 citationsauthor #5
Label-free drug screening assay multiplexed with an orthogonal time-resolved fluorescence labeled assay.
20192 citationsauthor #1
Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase
201820 citationsauthor #1
Opicapone, a Novel Catechol‐O‐Methyltranferase Inhibitor (COMT) to Manage the Symptoms of Parkinson's Disease
20181 citationsauthor #1
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.
20176 citationsauthor #11
B‐973, a novel piperazine positive allosteric modulator of the &agr;7 nicotinic acetylcholine receptor
201721 citationsauthor #12
Synthesis and structure–activity relationships of ionizable 1,3,4-oxadiazol-2(3H)-ones as peripherally selective FAAH inhibitors with improved aqueous solubility
20163 citationsauthor #8
A fluorescence polarization based assay for the identification and characterization of polymerase inhibitors.
20164 citationsauthor #2
Development of a spontaneously active dorsal root ganglia assay using multiwell multielectrode arrays.
201650 citationsauthor #4
Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain
201679 citationsauthor #51
A novel cell-based duplex high-throughput screening assay combining fluorescent Ca(2+) measurement with homogeneous time-resolved fluorescence technology.
20162 citationsauthor #1
Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist
201537 citationsauthor #7
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
201514 citationsauthor #3
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
2014100 citationsauthor #1
CHAPTER 4:Catechol‐O‐Methyl‐Transferase Inhibitors: Present Problems and Relevance of the New Ones
201313 citationsauthor #2
Selective, Direct Activation of High-Conductance, Calcium-Activated Potassium Channels Causes Smooth Muscle Relaxation
201224 citationsauthor #9
5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)- [1,2,4]oxadiazol-5yl]-2-hydroxy-3-methoxy-1-nitrobenzene as an intermediate to prepare a catechol-o-methyltransferease inhibitor
20120 citationsauthor #2
The Inwardly Rectifying Potassium Channel Kir1.1: Development of Functional Assays to Identify and Characterize Channel Inhibitors
201219 citationsauthor #8
Identification of Novel and Selective KV2 Channel Inhibitors
201124 citationsauthor #7
Design, synthesis, and structure–activity relationships of 1,3,4-oxadiazol-2(3H)-ones as novel FAAH inhibitors
201129 citationsauthor #1
A Miniaturized Homogenous Assay of Mitochondrial Membrane Potential
20113 citationsauthor #3
A Pharmacologically Validated, High-Capacity, Functional Thallium Flux Assay for the Human Ether-à-go-go Related Gene Potassium Channel
201034 citationsauthor #7
Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.
201016 citationsauthor #10
The chemistry of catechol-O-methyltransferase inhibitors.
201013 citationsauthor #2
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.
2010158 citationsauthor #1
Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
200910 citationsauthor #4
High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
200913 citationsauthor #2
Nitrokatekolforbindelser, use thereof and processes for preparing the compounds and pharmaceutical compositions containing them.
20080 citationsauthor #2
Efficient synthesis of 2-(trifluoromethyl)nicotinic acid derivatives from simple fluorinated precursors.
200836 citationsauthor #1
High-throughput analysis of drug binding interactions for the human cardiac channel , Kv 1
20080 citationsauthor #2
Miniaturization and HTS of a FRET-Based Membrane Potential Assay for Kir Channel Inhibitors
200830 citationsauthor #7
Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure
200836 citationsauthor #2
Kv1.5 Potassium Channel Inhibitors for the Treatment and Prevention of Atrial Fibrillation
20080 citationsauthor #2
Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
20070 citationsauthor #2
Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
200687 citationsauthor #7
Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
200613 citationsauthor #5
Nitrocatecholderivater comt inhibitors as
20060 citationsauthor #3
In vitro characterization of novel NR2B selective NMDA receptor antagonists.
200516 citationsauthor #1
Kinetic characterization of novel NR2B antagonists using fluorescence detection of calcium flux.
200410 citationsauthor #3
High Throughput Assay Technologies for Ion Channel Drug Discovery
2004122 citationsauthor #3
High Throughput Ion-Channel Pharmacology: Planar-Array-Based Voltage Clamp
2003119 citationsauthor #1
An improved design of fluorophilic molecules: prediction of the ln P fluorous partition coefficient, fluorophilicity, using 3D QSAR descriptors and neural networks
200176 citationsauthor #1
Potassium-dependent Changes in the Conformation of the Kv2.1 Potassium Channel Pore
199990 citationsauthor #3
Contribution of the selectivity filter to inactivation in potassium channels.
1999182 citationsauthor #1
Influence of non-P region domains on selectivity filter properties in voltage-gated K+ channels.
199811 citationsauthor #2
The Interaction of Na+ and K+ in Voltage-gated Potassium Channels
199868 citationsauthor #1
Role of the selectivity filter in inactivation of voltage-gated K+ channels
19980 citationsauthor #1
Modulation of C-type inactivation by K+ at the potassium channel selectivity filter.
1998153 citationsauthor #1
The Interaction of Na (cid:49) and K (cid:49) in Voltage-gated Potassium Channels Evidence for Cation Binding Sites of Different Affinity
19982 citationsauthor #1

TIMELINE

1998 234 citations

1999 272 citations

2001 76 citations

2003 119 citations

2004 132 citations

2005 16 citations

2006 100 citations

2007 0 citations

2008 102 citations

2009 23 citations

2010 221 citations

2011 56 citations

2012 43 citations

2013 13 citations

2014 100 citations

2015 51 citations

2016 138 citations

2017 27 citations

2018 21 citations

2019 2 citations

2021 6 citations

2022 7 citations

2023 0 citations

L. Kiss

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT